Unicycive Therapeutics, Inc. (NASDAQ:UNCY) Given Consensus Recommendation of “Hold” by Brokerages

Shares of Unicycive Therapeutics, Inc. (NASDAQ:UNCY) have received a consensus recommendation of “Hold” from the seven analysts that are presently covering the firm, Marketbeat.com reports. Two investment analysts have rated the stock with a sell recommendation and five have issued a buy recommendation on the company. The average twelve-month price objective among analysts that have updated their coverage on the stock in the last year is $18.25.

Several brokerages have recently issued reports on UNCY. Wall Street Zen upgraded Unicycive Therapeutics from a “sell” rating to a “hold” rating in a research note on Saturday, August 15th. Benchmark reduced their target price on shares of Unicycive Therapeutics from $18.00 to $13.00 and set a “speculative buy” rating on the stock in a report on Wednesday, July 1st. Weiss Ratings raised shares of Unicycive Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a report on Tuesday, June 9th. B. Riley Financial reiterated a “buy” rating and issued a $20.00 price target (down from $22.00) on shares of Unicycive Therapeutics in a research note on Wednesday, August 12th. Finally, HC Wainwright lowered their price target on shares of Unicycive Therapeutics from $22.00 to $15.00 and set a “buy” rating for the company in a report on Tuesday, June 30th.

Unicycive Therapeutics Stock Performance

Shares of UNCY opened at $5.58 on Thursday. The company’s 50-day simple moving average is $5.84 and its 200-day simple moving average is $6.61. Unicycive Therapeutics has a 1 year low of $3.71 and a 1 year high of $8.74. The stock has a market capitalization of $155.40 million, a PE ratio of -3.19 and a beta of 1.79.

Unicycive Therapeutics (NASDAQ:UNCY) last issued its quarterly earnings results on Wednesday, August 12th. The company reported ($0.06) EPS for the quarter, beating the consensus estimate of ($0.47) by $0.41. On average, sell-side analysts predict that Unicycive Therapeutics will post -1.17 earnings per share for the current year.

Hedge Funds Weigh In On Unicycive Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Millennium Management LLC acquired a new stake in Unicycive Therapeutics in the fourth quarter valued at $5,856,000. Vivo Capital LLC boosted its position in shares of Unicycive Therapeutics by 57.4% during the 3rd quarter. Vivo Capital LLC now owns 1,789,916 shares of the company’s stock worth $7,804,000 after acquiring an additional 652,901 shares in the last quarter. Cantor Fitzgerald L. P. purchased a new position in shares of Unicycive Therapeutics in the 4th quarter valued at about $1,154,000. Dimensional Fund Advisors LP purchased a new position in shares of Unicycive Therapeutics in the 1st quarter valued at about $940,000. Finally, Squarepoint Ops LLC acquired a new stake in shares of Unicycive Therapeutics during the 3rd quarter worth about $512,000. Institutional investors and hedge funds own 40.42% of the company’s stock.

Unicycive Therapeutics Company Profile

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.